{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T19:16:49Z","timestamp":1790363809791,"version":"4.1.0"},"reference-count":96,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T00:00:00Z","timestamp":1620172800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000862","name":"Doris Duke Charitable Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000862","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology and Allergy Clinics of North America"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.iac.2021.04.011","type":"journal-article","created":{"date-parts":[[2021,6,5]],"date-time":"2021-06-05T02:40:03Z","timestamp":1622860803000},"page":"347-359","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Innate Immune Regulation of Dermatitis"],"prefix":"10.1016","volume":"41","author":[{"given":"Damien","family":"Abreu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian S.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.iac.2021.04.011_bib1","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nature10851","article-title":"Skin infection generates non-migratory memory CD8+ T(RM) cells providing global skin immunity","volume":"483","author":"Jiang","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.iac.2021.04.011_bib2","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/nri.2015.3","article-title":"Tissue-resident memory T\u00a0cells: local specialists in immune defence","volume":"16","author":"Mueller","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.iac.2021.04.011_bib3","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/s41577-019-0162-3","article-title":"T\u00a0cells and the skin: from protective immunity to inflammatory skin disorders","volume":"19","author":"Ho","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.iac.2021.04.011_bib4","doi-asserted-by":"crossref","first-page":"4031","DOI":"10.1172\/JCI93396","article-title":"Clinically resolved psoriatic lesions contain psoriasis-specific IL-17-producing \u03b1\u03b2 T\u00a0cell clones","volume":"127","author":"Matos","year":"2017","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.iac.2021.04.011_bib5","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nature21379","article-title":"Survival of tissue-resident memory T\u00a0cells requires exogenous lipid uptake and metabolism","volume":"543","author":"Pan","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.iac.2021.04.011_bib6","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.jaci.2014.11.001","article-title":"The 3 major types of innate and adaptive cell-mediated effector immunity","volume":"135","author":"Annunziato","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2021.04.011_bib7","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrd4624","article-title":"Targeting key proximal drivers of type 2 inflammation in disease","volume":"15","author":"Gandhi","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.iac.2021.04.011_bib8","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev.iy.12.040194.001303","article-title":"Lymphokine production by human T\u00a0cells in disease states","volume":"12","author":"Romagnani","year":"1994","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.iac.2021.04.011_bib9","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.smim.2014.06.003","article-title":"Host protective roles of type 2 immunity: parasite killing and tissue repair, flip sides of the same coin","volume":"26","author":"Allen","year":"2014","journal-title":"Semin Immunol"},{"key":"10.1016\/j.iac.2021.04.011_bib10","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.immuni.2013.10.006","article-title":"Bee venom phospholipase A2 induces a primary type 2 response that is dependent on the receptor ST2 and confers protective immunity","volume":"39","author":"Palm","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.iac.2021.04.011_bib11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.alit.2015.09.002","article-title":"Mast cells and IgE in defense against venoms: Possible \"good side\" of allergy?","volume":"65","author":"Galli","year":"2016","journal-title":"Allergol Int"},{"key":"10.1016\/j.iac.2021.04.011_bib12","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/ni1254","article-title":"Interleukin 17-producing CD4+ effector T\u00a0cells develop via a lineage distinct from the T helper type 1 and 2 lineages","volume":"6","author":"Harrington","year":"2005","journal-title":"Nat Immunol"},{"key":"10.1016\/j.iac.2021.04.011_bib13","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/imr.12027","article-title":"IL-22, not simply a Th17 cytokine","volume":"252","author":"Rutz","year":"2013","journal-title":"Immunol Rev"},{"key":"10.1016\/j.iac.2021.04.011_bib14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s13317-013-0057-4","article-title":"The Th17 axis in psoriatic disease: pathogenetic and therapeutic implications","volume":"5","author":"Marinoni","year":"2014","journal-title":"Auto Immun Highlights"},{"key":"10.1016\/j.iac.2021.04.011_bib15","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.7927.1","article-title":"Recent advances in understanding psoriasis","volume":"5","author":"Eberle","year":"2016","journal-title":"F1000Research"},{"key":"10.1016\/j.iac.2021.04.011_bib16","doi-asserted-by":"crossref","first-page":"e321","DOI":"10.1111\/bjd.15533","article-title":"Interleukin (IL)-17A and IL-22-producing neutrophils in psoriatic skin","volume":"177","author":"Dyring-Andersen","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.iac.2021.04.011_bib17","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Menter","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.iac.2021.04.011_bib18","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.det.2018.02.014","article-title":"Immunomodulating agents as antipruritics","volume":"36","author":"Erickson","year":"2018","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.iac.2021.04.011_bib19","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1016\/j.jid.2019.08.437","article-title":"Psoriasis: past, present, and future","volume":"139","author":"Billi","year":"2019","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.iac.2021.04.011_bib20","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(06)69283-0","article-title":"Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys","volume":"368","author":"Asher","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.iac.2021.04.011_bib21","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1001\/archdermatol.2011.178","article-title":"The impact of pruritus on quality of life: the skin equivalent of pain","volume":"147","author":"Kini","year":"2011","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.iac.2021.04.011_bib22","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJMcp1208814","article-title":"Clinical practice. Chronic pruritus","volume":"368","author":"Yosipovitch","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iac.2021.04.011_bib23","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.anai.2019.04.020","article-title":"Comorbidities and the impact of atopic dermatitis","volume":"123","author":"Silverberg","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.iac.2021.04.011_bib24","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.anai.2018.07.006","article-title":"Patient burden and quality of life in atopic dermatitis in US adults: A population-based cross-sectional study","volume":"121","author":"Silverberg","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.iac.2021.04.011_bib25","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11882-015-0592-3","article-title":"The immunologic mechanisms of eosinophilic esophagitis","volume":"16","author":"Hill","year":"2016","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.iac.2021.04.011_bib26","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s12016-011-8252-4","article-title":"IgE, mast cells, and eosinophils in atopic dermatitis","volume":"41","author":"Liu","year":"2011","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.iac.2021.04.011_bib27","first-page":"47","article-title":"Peripheral blood eosinophilia in atopic dermatitis","volume":"16","author":"Jenerowicz","year":"2007","journal-title":"Acta Dermatovenerol Alp Pannonica Adriat"},{"key":"10.1016\/j.iac.2021.04.011_bib28","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1172\/JCI117408","article-title":"Differential in\u00a0situ cytokine gene expression in acute versus chronic atopic dermatitis","volume":"94","author":"Hamid","year":"1994","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.iac.2021.04.011_bib29","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/ni805","article-title":"Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP","volume":"3","author":"Soumelis","year":"2002","journal-title":"Nat Immunol"},{"key":"10.1016\/j.iac.2021.04.011_bib30","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1046\/j.0022-202x.2001.01484.x","article-title":"Expression of interleukin-4 in the epidermis of transgenic mice results in a pruritic inflammatory skin disease: an experimental animal model to study atopic dermatitis","volume":"117","author":"Chan","year":"2001","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.iac.2021.04.011_bib31","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/ni.2584","article-title":"Cutaneous immunosurveillance and regulation of inflammation by group 2 innate lymphoid cells","volume":"14","author":"Roediger","year":"2013","journal-title":"Nat Immunol"},{"key":"10.1016\/j.iac.2021.04.011_bib32","doi-asserted-by":"crossref","first-page":"170ra16","DOI":"10.1126\/scitranslmed.3005374","article-title":"TSLP elicits IL-33-independent innate lymphoid cell responses to promote skin inflammation","volume":"5","author":"Kim","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.iac.2021.04.011_bib33","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/iid3.161","article-title":"Group 2 innate lymphoid cells are elevated and activated in chronic rhinosinusitis with nasal polyps","volume":"5","author":"Poposki","year":"2017","journal-title":"Immun Inflamm Dis"},{"key":"10.1016\/j.iac.2021.04.011_bib34","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.it.2015.01.005","article-title":"Lung ILC2s link innate and adaptive responses in allergic inflammation","volume":"36","author":"Martinez-Gonzalez","year":"2015","journal-title":"Trends Immunol"},{"key":"10.1016\/j.iac.2021.04.011_bib35","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.jaci.2019.11.047","article-title":"Progression of acute-to-chronic atopic dermatitis is associated with quantitative rather than qualitative changes in cytokine responses","volume":"145","author":"Tsoi","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2021.04.011_bib36","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jaci.2017.01.008","article-title":"Clinical phenotypes and endophenotypes of atopic dermatitis: Where are we, and where should we go?","volume":"139","author":"Bieber","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2021.04.011_bib37","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/j.jaci.2017.01.011","article-title":"The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies","volume":"139","author":"Brunner","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2021.04.011_bib38","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S0091-6749(96)80161-8","article-title":"Biphasic response against aeroallergen in atopic dermatitis showing a switch from an initial TH2 response to a TH1 response in\u00a0situ: an immunocytochemical study","volume":"97","author":"Thepen","year":"1996","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2021.04.011_bib39","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0140-6736(94)90879-6","article-title":"Lesional expression of interferon-gamma in atopic eczema","volume":"343","author":"Grewe","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.iac.2021.04.011_bib40","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two Phase 3 Trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iac.2021.04.011_bib41","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1001\/jamadermatol.2020.0079","article-title":"Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b randomized clinical trial","volume":"156","author":"Guttman-Yassky","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.iac.2021.04.011_bib42","first-page":"1","article-title":"Review and analysis of biologic therapies currently in phase II and phase III clinical trials for atopic dermatitis","author":"Uppal","year":"2020","journal-title":"J\u00a0Dermatol Treat"},{"key":"10.1016\/j.iac.2021.04.011_bib43","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1038\/jid.2008.295","article-title":"Transgenic expression of interleukin-13 in the skin induces a pruritic dermatitis and skin remodeling","volume":"129","author":"Zheng","year":"2009","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.iac.2021.04.011_bib44","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jaci.2013.10.048","article-title":"A\u00a0sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: Involvement of TRPV1 and TRPA1","volume":"133","author":"Cevikbas","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2021.04.011_bib45","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/ni1084","article-title":"Interleukin 31, a cytokine produced by activated T\u00a0cells, induces dermatitis in mice","volume":"5","author":"Dillon","year":"2004","journal-title":"Nat Immunol"},{"key":"10.1016\/j.iac.2021.04.011_bib46","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jaci.2005.10.033","article-title":"IL-31: a new link between T\u00a0cells and pruritus in atopic skin inflammation","volume":"117","author":"Sonkoly","year":"2006","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2021.04.011_bib47","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.jaci.2008.05.047","article-title":"Correlation of IL-31 serum levels with severity of atopic dermatitis","volume":"122","author":"Raap","year":"2008","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2021.04.011_bib48","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/bjd.14207","volume":"174","author":"Nemoto","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.iac.2021.04.011_bib49","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1606490","article-title":"Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis","volume":"376","author":"Ruzicka","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iac.2021.04.011_bib50","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJMoa1917006","article-title":"Trial of nemolizumab and topical agents for atopic dermatitis with pruritus","volume":"383","author":"Kabashima","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iac.2021.04.011_bib51","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cell.2017.08.006","article-title":"Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch","volume":"171","author":"Oetjen","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.iac.2021.04.011_bib52","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nn.3881","article-title":"Unbiased classification of sensory neuron types by large-scale single-cell RNA sequencing","volume":"18","author":"Usoskin","year":"2015","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.iac.2021.04.011_bib53","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0167-4889(02)00318-X","article-title":"Structure, binding, and antagonists in the IL-4\/IL-13 receptor system","volume":"1592","author":"Mueller","year":"2002","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.iac.2021.04.011_bib54","doi-asserted-by":"crossref","first-page":"e13222","DOI":"10.1111\/dth.13222","article-title":"Dupilumab for prurigo nodularis: Case series and review of the literature","volume":"33","author":"Holm","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.iac.2021.04.011_bib55","first-page":"72","article-title":"Chronic pruritus responding to dupilumab-a case series","volume":"6","author":"Zhai","year":"2019","journal-title":"Medicines (Basel)"},{"issue":"1","key":"10.1016\/j.iac.2021.04.011_bib56","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/09546634.2019.1689227","article-title":"Dupilumab use in dermatologic conditions beyond atopic dermatitis - a systematic review","volume":"32","author":"Hendricks","year":"2019","journal-title":"J\u00a0Dermatol Treat"},{"key":"10.1016\/j.iac.2021.04.011_bib57","doi-asserted-by":"crossref","DOI":"10.5070\/D32511046147","article-title":"Dupilumab for bullous pemphigoid with intractable pruritus","volume":"25","author":"Seidman","year":"2019","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.iac.2021.04.011_bib58","doi-asserted-by":"crossref","first-page":"13921","DOI":"10.1073\/pnas.1307321110","article-title":"Skin-specific expression of IL-33 activates group 2 innate lymphoid cells and elicits atopic dermatitis-like inflammation in mice","volume":"110","author":"Imai","year":"2013","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.iac.2021.04.011_bib59","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/jid.2012.239","article-title":"TSLP produced by keratinocytes promotes allergen sensitization through skin and thereby triggers atopic march in mice","volume":"133","author":"Leyva-Castillo","year":"2013","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.iac.2021.04.011_bib60","doi-asserted-by":"crossref","first-page":"E7572.e9","DOI":"10.1073\/pnas.1606608113","article-title":"IL-33\/ST2 signaling excites sensory neurons and mediates itch response in a mouse model of poison ivy contact allergy","volume":"113","author":"Liu","year":"2016","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.iac.2021.04.011_bib61","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.cell.2013.08.057","article-title":"The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch","volume":"155","author":"Wilson","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.iac.2021.04.011_bib62","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax2945","article-title":"Proof-of-concept clinical trial of etokimab shows a key role for IL-33 in atopic dermatitis pathogenesis","volume":"11","author":"Chen","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.iac.2021.04.011_bib63","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1001\/jamadermatol.2019.2855","article-title":"Efficacy and safety of oral janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a phase 2 randomized clinical trial","volume":"155","author":"Gooderham","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.iac.2021.04.011_bib64","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/bjd.18898","article-title":"Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials","volume":"183","author":"Simpson","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.iac.2021.04.011_bib65","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.jaad.2018.01.018","article-title":"Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study","volume":"80","author":"Guttman-Yassky","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.iac.2021.04.011_bib66","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.jaci.2019.11.025","article-title":"Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial","volume":"145","author":"Guttman-Yassky","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2021.04.011_bib67","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.jaad.2020.02.009","article-title":"Effects of ruxolitinib cream on pruritus and quality of life in atopic dermatitis: Results from a phase 2, randomized, dose-ranging, vehicle- and active-controlled study","volume":"82","author":"Kim","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.iac.2021.04.011_bib68","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jaci.2019.08.042","article-title":"Treatment of atopic dermatitis with ruxolitinib cream (JAK1\/JAK2 inhibitor) or triamcinolone cream","volume":"145","author":"Kim","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2021.04.011_bib69","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/bjd.18469","article-title":"Efficacy and safety of topical delgocitinib in patients with chronic hand eczema: data from a randomized, double-blind, vehicle-controlled phase IIa study","volume":"182","author":"Worm","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.iac.2021.04.011_bib70","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.jaci.2019.08.004","article-title":"Phase 2 clinical study of delgocitinib ointment in pediatric patients with atopic dermatitis","volume":"144","author":"Nakagawa","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2021.04.011_bib71","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.iac.2016.08.014","article-title":"Allergic Contact Dermatitis","volume":"37","author":"Kostner","year":"2017","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.iac.2021.04.011_bib72","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.immuni.2005.10.008","article-title":"Epidermal langerhans cell-deficient mice develop enhanced contact hypersensitivity","volume":"23","author":"Kaplan","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.iac.2021.04.011_bib73","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.immuni.2012.03.018","article-title":"Human epidermal Langerhans cells maintain immune homeostasis in skin by activating skin resident regulatory T\u00a0cells","volume":"36","author":"Seneschal","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.iac.2021.04.011_bib74","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1046\/j.1523-1747.2003.12093.x","article-title":"Afferent and efferent phases of allergic contact dermatitis (ACD) can be induced after a single skin contact with haptens: evidence using a mouse model of primary ACD","volume":"120","author":"Saint-Mezard","year":"2003","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.iac.2021.04.011_bib75","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.immuni.2019.03.013","article-title":"Activation of mast-cell-expressed mas-related g-protein-coupled receptors drives non-histaminergic itch","volume":"50","author":"Meixiong","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.iac.2021.04.011_bib76","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/jid.2013.351","article-title":"Histamine H(4) receptor antagonists ineffective against itch and skin inflammation in atopic dermatitis mouse model","volume":"134","author":"Kamo","year":"2014","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.iac.2021.04.011_bib77","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature14022","article-title":"Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions","volume":"519","author":"McNeil","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.iac.2021.04.011_bib78","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0092-8674(01)00483-4","article-title":"A\u00a0diverse family of GPCRs expressed in specific subsets of nociceptive sensory neurons","volume":"106","author":"Dong","year":"2001","journal-title":"Cell"},{"key":"10.1016\/j.iac.2021.04.011_bib79","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/j.cell.2009.11.034","article-title":"Sensory neuron-specific GPCR Mrgprs are itch receptors mediating chloroquine-induced pruritus","volume":"139","author":"Liu","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.iac.2021.04.011_bib80","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ejphar.2011.06.027","article-title":"G\u00a0protein coupled receptor specificity for C3a and compound 48\/80-induced degranulation in human mast cells: roles of Mas-related genes MrgX1 and MrgX2","volume":"668","author":"Kashem","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.iac.2021.04.011_bib81","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.bbrc.2006.08.177","article-title":"Immunoglobulin E-independent activation of mast cell is mediated by Mrg receptors","volume":"349","author":"Tatemoto","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.iac.2021.04.011_bib82","doi-asserted-by":"crossref","first-page":"44739","DOI":"10.1074\/jbc.M111.277152","article-title":"Mas-related gene X2 (MrgX2) is a novel G protein-coupled receptor for the antimicrobial peptide LL-37 in human mast cells: resistance to receptor phosphorylation, desensitization, and internalization","volume":"286","author":"Subramanian","year":"2011","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.iac.2021.04.011_bib83","doi-asserted-by":"crossref","first-page":"11628","DOI":"10.1038\/s41598-018-29965-8","article-title":"MRGPRX2-mediated mast cell response to drugs used in perioperative procedures and anaesthesia","volume":"8","author":"Navin\u00e9s-Ferrer","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.iac.2021.04.011_bib84","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jaci.2016.04.051","article-title":"Roles of Mas-related G protein-coupled receptor X2 on mast cell-mediated host defense, pseudoallergic drug reactions, and chronic inflammatory diseases","volume":"138","author":"Subramanian","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2021.04.011_bib85","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.bbrc.2005.03.088","article-title":"Identification of MrgX2 as a human G-protein-coupled receptor for proadrenomedullin N-terminal peptides","volume":"330","author":"Kamohara","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.iac.2021.04.011_bib86","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1016\/j.celrep.2019.02.089","article-title":"Nppb neurons are sensors of mast cell-induced itch","volume":"26","author":"Solinski","year":"2019","journal-title":"Cell Rep"},{"key":"10.1016\/j.iac.2021.04.011_bib87","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1111\/all.13397","article-title":"The EAACI\/GA2LEN\/EDF\/WAO guideline for the definition, classification, diagnosis and management of urticaria","volume":"73","author":"Zuberbier","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.iac.2021.04.011_bib88","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000237635","article-title":"New aspects of mast cell biology","volume":"114","author":"Dvorak","year":"1997","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.iac.2021.04.011_bib89","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2340\/0001555576295297","article-title":"Acute urticaria: clinical aspects and therapeutic responsiveness","volume":"76","author":"Zuberbier","year":"1996","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.iac.2021.04.011_bib90","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/j.1365-2222.2006.02494.x","article-title":"Evidence of in\u00a0vivo basophil activation in chronic idiopathic urticaria","volume":"36","author":"Vasagar","year":"2006","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.iac.2021.04.011_bib91","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa1215372","article-title":"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria","volume":"368","author":"Maurer","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iac.2021.04.011_bib92","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1900408","article-title":"Ligelizumab for Chronic Spontaneous Urticaria","volume":"381","author":"Maurer","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iac.2021.04.011_bib93","first-page":"187","article-title":"Omalizumab re-treatment rates in chronic spontaneous urticaria","volume":"52","author":"Khan","year":"2020","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2021.04.011_bib94","series-title":"Contact urticaria. StatPearls","author":"Vethachalam","year":"2020"},{"key":"10.1016\/j.iac.2021.04.011_bib95","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1097\/01.SMJ.0000097887.04639.39","article-title":"Molecular mechanisms of allergic disease","volume":"96","author":"Venarske","year":"2003","journal-title":"South Med J"},{"key":"10.1016\/j.iac.2021.04.011_bib96","first-page":"5","article-title":"Urticaria and urticaria related skin condition\/disease in children","volume":"40","author":"Novembre","year":"2008","journal-title":"Eur Ann Allergy Clin Immunol"}],"container-title":["Immunology and Allergy Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856121000369?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856121000369?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:44:47Z","timestamp":1760179487000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889856121000369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":96,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S0889856121000369"],"URL":"https:\/\/doi.org\/10.1016\/j.iac.2021.04.011","relation":{},"ISSN":["0889-8561"],"issn-type":[{"value":"0889-8561","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Innate Immune Regulation of Dermatitis","name":"articletitle","label":"Article Title"},{"value":"Immunology and Allergy Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iac.2021.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}